⌕
Janux Therapeutics · JANX · Nasdaq
Tenet 74 · Solid
Compare
$10.92−3.96%At closeTenet 74 · Solid
$10.92−0.45 (−3.96%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD

Janux Therapeutics (JANX) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Seeking AlphaNov 9, 2026 · 17:01 ET
Janux Therapeutics, Inc. (JANX) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy Transcript

Janux Therapeutics, Inc. ( JANX ) Discusses JANX011 Phase 1 Healthy Volunteer Data and Autoimmune Development Strategy November 9, 2026 8:30 AM EST Company Participants David Campbell - President, Co-Founder, CEO & Direc…

● Business WireNov 9, 2026 · 08:30 ETCOMPANY'S OWN WORDS
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced initial clinical results from …

● Zacks Investment ResearchNov 5, 2026 · 18:11 ET
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates

Janux Therapeutics, Inc. (JANX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.39 per share a year ago.…

● Business WireNov 5, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quart…

● Business WireNov 2, 2026 · 16:02 ETCOMPANY'S OWN WORDS
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biopharmaceutical company developing next-generation immunotherapies, today announced that it will host a virtual event on Monday, Nov…

● Defense WorldOct 13, 2026 · 03:15 ET
Janux Therapeutics (NASDAQ:JANX) and Zai Lab (NASDAQ:ZLAB) Head-To-Head Survey

Zai Lab (NASDAQ: ZLAB - Get Free Report) and Janux Therapeutics (NASDAQ: JANX - Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of…

● Defense WorldOct 6, 2026 · 06:15 ET
Head-To-Head Review: Janux Therapeutics (NASDAQ:JANX) and Roivant Sciences (NASDAQ:ROIV)

Janux Therapeutics (NASDAQ: JANX - Get Free Report) and Roivant Sciences (NASDAQ: ROIV - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on t…

● Zacks Investment ResearchSep 15, 2026 · 11:15 ET
4 Prostate Cancer Drug Stocks to Watch During Awareness Month

Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts.…

● Business WireSep 14, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013

SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1…

● Zacks Investment ResearchAug 21, 2026 · 11:56 ET
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know

Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence.…

No upcoming events in the feeds.

Quiet tape today.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.